Abstract: The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.
Type:
Grant
Filed:
July 5, 2007
Date of Patent:
August 27, 2013
Assignees:
Universite de la Mediterranee AIX-Marseille II, Association Francaise Contre les Myophathies (AFM), Assistance Publique Hopitaux de Marseille, Universidad de Oviedo
Inventors:
Nicolas Levy, Pierre Cau, Carlos Lopez-Otin